Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 22
2026
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,928
-0.51%
|
$124,488
$21.77 P/Share
|
|
Jan 22
2026
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
3,371
-4.12%
|
$70,791
$21.77 P/Share
|
|
Jan 22
2026
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,064
-3.98%
|
$43,344
$21.77 P/Share
|
|
Jan 22
2026
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,797
-3.13%
|
$58,737
$21.77 P/Share
|
|
Jan 22
2026
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
7,832
-8.13%
|
$164,472
$21.77 P/Share
|
|
Jan 22
2026
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,287
-9.87%
|
$216,027
$21.77 P/Share
|
|
Jan 22
2026
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
7,725
-9.8%
|
$162,225
$21.77 P/Share
|
|
Jan 22
2026
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
27,192
-8.68%
|
$571,032
$21.77 P/Share
|
|
Jan 20
2026
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
909
-0.08%
|
$17,271
$19.79 P/Share
|
|
Jan 20
2026
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,334
-1.61%
|
$25,346
$19.79 P/Share
|
|
Jan 20
2026
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
726
-1.38%
|
$13,794
$19.79 P/Share
|
|
Jan 20
2026
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,882
-2.06%
|
$35,758
$19.79 P/Share
|
|
Jan 20
2026
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,892
-2.7%
|
$54,948
$19.79 P/Share
|
|
Jan 20
2026
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,203
-2.72%
|
$41,857
$19.79 P/Share
|
|
Jan 20
2026
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,182
-2.55%
|
$155,458
$19.79 P/Share
|
|
Jan 20
2026
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
2,475
-2.5%
|
$47,025
$19.79 P/Share
|
|
Jan 13
2026
|
Nur Nicholson Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,618
-3.13%
|
$57,596
$22.19 P/Share
|
|
Jan 13
2026
|
Cedric Francois Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,186
-3.07%
|
$224,092
$22.19 P/Share
|
|
Jan 13
2026
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,277
-0.2%
|
$50,094
$22.19 P/Share
|
|
Jan 13
2026
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
1,780
-2.1%
|
$39,160
$22.19 P/Share
|
|
Jan 13
2026
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
873
-1.63%
|
$19,206
$22.19 P/Share
|
|
Jan 13
2026
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,780
-5.52%
|
$127,160
$22.19 P/Share
|
|
Jan 13
2026
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,856
-3.48%
|
$84,832
$22.19 P/Share
|
|
Jan 07
2026
|
David O. Watson General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
888
+0.84%
|
$12,432
$14.95 P/Share
|
|
Jan 05
2026
|
Caroline Baumal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,020
-3.21%
|
$75,500
$25.53 P/Share
|
|
Jan 01
2026
|
Alec Machiels Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+2.03%
|
-
|
|
Jan 01
2026
|
Keli Walbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+31.83%
|
-
|
|
Jan 01
2026
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+20.61%
|
-
|
|
Jan 01
2026
|
Stephanie Monaghan O'Brien Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+23.67%
|
-
|
|
Jan 01
2026
|
Gerald Chan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+23.67%
|
-
|
|
Jan 01
2026
|
A. Sinclair Dunlop Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+4.7%
|
-
|
|
Jan 01
2026
|
Craig A Wheeler Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,961
+24.57%
|
-
|
|
Dec 16
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-4.6%
|
$120,000
$24.49 P/Share
|
|
Nov 17
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-4.4%
|
$100,000
$20.06 P/Share
|
|
Oct 21
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-8.27%
|
$280,000
$28.03 P/Share
|
|
Oct 21
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+7.64%
|
$100,000
$10.03 P/Share
|
|
Oct 16
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-4.21%
|
$125,000
$25.22 P/Share
|
|
Oct 10
2025
|
A. Sinclair Dunlop Director |
SELL
Other acquisition or disposition
|
Indirect |
3,837
-100.0%
|
-
|
|
Oct 10
2025
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
31,092
-89.01%
|
$715,116
$23.72 P/Share
|
|
Sep 30
2025
|
A. Sinclair Dunlop Director |
SELL
Other acquisition or disposition
|
Indirect |
3,837
-11.29%
|
-
|
|
Sep 30
2025
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
31,092
-47.78%
|
$684,024
$22.58 P/Share
|
|
Sep 19
2025
|
A. Sinclair Dunlop Director |
SELL
Other acquisition or disposition
|
Indirect |
3,837
-5.57%
|
-
|
|
Sep 19
2025
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
31,092
-31.09%
|
$684,024
$22.95 P/Share
|
|
Sep 16
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-4.04%
|
$120,000
$24.34 P/Share
|
|
Sep 15
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
189
-0.35%
|
$4,536
$24.19 P/Share
|
|
Sep 10
2025
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Indirect |
20,000
-28.52%
|
$520,000
$26.17 P/Share
|
|
Sep 08
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-14.21%
|
$270,000
$27.83 P/Share
|
|
Sep 08
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,729
-22.78%
|
$883,683
$27.86 P/Share
|
|
Sep 08
2025
|
Timothy Eugene Sullivan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+9.45%
|
$150,000
$10.03 P/Share
|
|
Sep 02
2025
|
James George Chopas VP/Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
548
-1.01%
|
$15,344
$28.08 P/Share
|